MTOR and renal cell carcinoma: Temsirolimus inhibits the mammalian target of rapamycin.[1] Survival benefits reported with Sorafenib and Sunitinib has led to their approval for advanced RCC by regulatory authorities.[2] With the advent of these promising drugs, prognostication of patients with renal cell carcinoma has gained immense importance since viable options for further treatment can be explored in high-risk groups.